(Q47634507)

4 February 2018

title

Medication for psychosis--consumption and consequences: the second Australian national survey of psychosis (English)

1 reference

4 February 2018

1 reference

Patsy Di Prinzio

6

0 references

Anna Waterreus

object named as

Anna Waterreus

1

0 references

Vera A Morgan

2

object named as

Vera A Morgan

1 reference

4 February 2018

Assen V Jablensky

5

object named as

Assen Jablensky

1 reference

4 February 2018

author name string

David Castle

3

1 reference

4 February 2018

Cherrie Galletly

4

1 reference

4 February 2018

Sonal Shah

7

1 reference

4 February 2018

publication date

11 June 2012

1 reference

4 February 2018

Australian and New Zealand Journal of Psychiatry

published in

1 reference

4 February 2018

volume

46

1 reference

4 February 2018

issue

8

1 reference

4 February 2018

page(s)

762-773

1 reference

4 February 2018

Antipsychotic polypharmacy in schizophrenia: benefits and risks

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

Antipsychotic use in Australia: the patients' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

Combination antipsychotics: pros, cons, and questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

People living with psychotic illness in 2010: the second Australian national survey of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

Side effects of atypical antipsychotics: a brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412450471

21 January 2018

Identifiers

DOI

10.1177/0004867412450471

1 reference

4 February 2018

1 reference

4 February 2018